



WHAT IS CLAIMED IS:

- 5 1. The compound which has the structure



10


2. The compound which has the structure



15


20

3. The compound which has the structure




5

4. The compound which has the structure



10


5. The compound which has the structure



15

20

6. The compound which has the structure:



5 wherein R is straight or branched alkyl of 1 to 10 carbon atoms, alkenyl of 2 to 10 carbon atoms, cycloalkyl of 3 to 10 carbon atoms and cycloalkenyl of 3 to 10 carbon atoms.

7. The compound according to claim 6 where R is $-\text{CH}_2\text{CH}_2\text{CH}_3$, $-\text{CH}(\text{CH}_3)_2$,
 10 $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$, or $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$.

8. A method of treating a warm-blooded animal affected by bacterial infections, which method comprises administering to said warm-blooded animal an effective amount of a compound of claim 1.

15

9. A method of treating a warm-blooded animal affected by bacterial infections, which method comprises administering to said warm-blooded animal an effective amount of a compound of claim 2.

20 10. A method of treating a warm-blooded animal affected by bacterial infections, which method comprises administering to said warm-blooded animal an effective amount of a compound of claim 3.


11. A method of treating a warm-blooded animal affected by bacterial infections,
 25 which method comprises administering to said warm-blooded animal an effective amount of a compound of claim 4.

12. A method of treating a warm-blooded animal affected by bacterial infections, which method comprises administering to said warm-blooded animal an effective amount of a compound of claim 5.
- 5 13. A method of treating a warm-blooded animal affected by bacterial infections, which method comprises administering to said warm-blooded animal an effective amount of a compound of claim 6.
- 10 14. A pharmaceutical composition comprising an effective amount of a compound of claim 1 together with a pharmaceutically acceptable carrier.
- 15 15. A pharmaceutical composition comprising an effective amount of a compound of claim 2 together with a pharmaceutically acceptable carrier.
- 16 16. A pharmaceutical composition comprising an effective amount of a compound of claim 3 together with a pharmaceutically acceptable carrier.
- 20 17. A pharmaceutical composition comprising an effective amount of a compound of claim 4 together with a pharmaceutically acceptable carrier.
- 25 18. A pharmaceutical composition comprising an effective amount of a compound of claim 5 together with a pharmaceutically acceptable carrier.
- 30 19. A pharmaceutical composition comprising an effective amount of a compound of claim 6 together with a pharmaceutically acceptable carrier.
20. A pharmaceutical or disinfectant composition which contains an effective antimicrobial, antiseptic or disinfectant amount of the compound of claim 1 as an active ingredient.

21. A pharmaceutical or disinfectant composition which contains an effective antimicrobial, antiseptic or disinfectant amount of a compound of claim 2 as an active ingredient.
- 5 22. A pharmaceutical or disinfectant composition which contains an effective antimicrobial, antiseptic or disinfectant amount of a compound of claim 3 as an active ingredient.
- 10 23. A pharmaceutical or disinfectant composition which contains an effective antimicrobial, antiseptic or disinfectant amount of a compound of claim 4 as an active ingredient.
- 15 24. A pharmaceutical or disinfectant composition which contains an effective antimicrobial, antiseptic or disinfectant amount of a compound of claim 5 as an active ingredient.
- 20 25. A pharmaceutical or disinfectant composition which contains an effective antimicrobial, antiseptic or disinfectant amount of a compound of claim 6 as an active ingredient.
- 25 26. A process for the preparation of antibiotics Cyan-416 A, Cyan-416 B, Cyan-416 C, Cyan-416 D, or Cyan-416 E, which comprises cultivating *Acremonium sp.* designated *NRRL30631* or a mutant thereof under aerobic conditions in a sterile liquid medium containing assimilable sources of carbon, nitrogen and inorganic anion and cation salts, until substantial antibiotic activity is imparted to said medium by the production of Cyan-416 A, Cyan-416 B, Cyan-416 C, Cyan-416 D, or Cyan-416 E, recovering and isolating said antibiotics.
- 30 27. The process according to claim 26 wherein said recovered antibiotics Cyan-416 A, Cyan-416 B, Cyan-416 C, Cyan-416 D, and Cyan-416 E are separated and purified by high pressure liquid chromatography, HPLC.


28. A process for the preparation of esters of the formula

5



wherein R is straight or branched alkyl of 1 to 10 carbon atoms, alkenyl of 2 to 10 carbon atoms, cycloalkyl of 3 to 10 carbon atoms and cycloalkenyl of 3 to 10 carbon atoms which comprises reacting an anhydride, $(R-C(O)-)_2O$ where R is straight and branched alkyl of 1 to 10 carbon atoms, alkenyl of 2 to 10 carbon atoms, cycloalkyl of 3 to 10 carbon atoms and cycloalkenyl of 3 to 10 carbon atoms in the presence of boron trifluoride diethyl etherate ($BF_3 \cdot Et_2O$) at about $0^\circ C$ with Cyan-416B of the formula


15



20


to afford an ester of the formula

5




29. A process for the preparation of Cyan-416B of the formula

10




which comprises hydrolyzing with acid a compound of the formula

15



where R is straight and branched alkyl of 1 to 10 carbon atoms, alkenyl of 2 to 10
 5 carbon atoms, cycloalkyl of 3 to 10 carbon atoms and cycloalkenyl of 3 to 10 carbon
 atoms to give a compound of the formula



10 30. The process according to claim 29 wherein the acid is hydrochloric acid.

31. A process for the preparation of antibiotics Cyan-416A, Cyan-416B, Cyan-416C,
 Cyan-416D, or Cyan-416E, which comprises cultivating *Acremonium sp.* Designated
 NRRL30631 or a mutant thereof on moist milk filter paper on the surface of a solid
 15 agar medium containing malt extract, peptone and yeast extract and incubated under
 stationary conditions at about 22°C until substantial antibiotic activity is imparted to
 said medium by the production of Cyan-416A, Cyan-416B, Cyan-416C, Cyan-416D,
 or Cyan-416E, recovering and isolating said antibiotics.

32. The process according to claim 31 wherein said recovered antibiotics Cyan-416A, Cyan-4156B, Cyan-416C, Cyan-416D, and Cyan-416E are separated and purified by high pressure liquid chromatography, HPLC.